Kim Kuhar
Internal Medicine · Silverdale, PANPI 1508898396
Payments from drug & device makers
Across 111 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$352
- AstraZeneca$265
- AbbVie$231
- Pfizer$210
- Abbott$190
- GSK$165
- plus $834 from 16 others
What the payments were for
- Food & beverage$2,06492%
- Education$1848%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 11 | $352 |
| AstraZeneca | 16 | $265 |
| AbbVie(2 entities) | 14 | $231 |
| Pfizer | 11 | $210 |
| Abbott | 9 | $190 |
| GSK | 8 | $165 |
| Novo Nordisk | 8 | $143 |
| Exact Sciences | 6 | $131 |
| Lilly USA, LLC | 5 | $89 |
| Corcept Therapeutics | 3 | $87 |
| Bayer | 4 | $74 |
| Amgen | 3 | $64 |
| Boehringer Ingelheim | 2 | $45 |
| Johnson & Johnson | 2 | $38 |
| Merck | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Vertos Medical, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $14 |
How this compares
$2,248 in reported general payments places this provider in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 88 | $92,810 |
| FarxigaDapagliflozin Propanediol | 107 | $83,465 |
| EliquisApixaban | 97 | $62,133 |
| MounjaroTirzepatide | 45 | $51,319 |
| JardianceEmpagliflozin | 54 | $44,846 |
| MyrbetriqMirabegron | 36 | $26,271 |
| TrulicityDulaglutide | 16 | $22,613 |
| JanuviaSitagliptin Phosphate | 27 | $18,528 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $18,386 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $14,642 |
| XareltoRivaroxaban | 18 | $11,615 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,444 |
| GemtesaVibegron | 14 | $9,035 |
| SynthroidLevothyroxine Sodium | 102 | $7,543 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 28 | $6,124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $143 | $92,81088 claims |
| AstraZenecaFarxiga | $265 | $83,465107 claims |
| Lilly USA, LLCMounjaro, Trulicity | $89 | $73,93161 claims |
| PfizerEliquis | $210 | $62,13397 claims |
| Boehringer IngelheimJardiance | $45 | $44,84654 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $165 | $27,83039 claims |
| Astellas Pharma US IncMyrbetriq | $352 | $26,27136 claims |
| MerckJanuvia | $28 | $18,52827 claims |
| Johnson & JohnsonXarelto | $38 | $11,61518 claims |
| AbbVieSynthroid, Lumigan | $231 | $10,438113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Silverdale
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.